vdac-1 Antibody

What is VDAC1 and why is it important in cellular research?

VDAC1 (Voltage-Dependent Anion Channel 1) is a pore-forming protein primarily located in the mitochondrial outer membrane that plays a crucial role as a gatekeeper for the passage of metabolites, nucleotides, and ions between the cytosol and mitochondria. It is an essential regulator of cellular metabolism and plays a significant role in the early stages of apoptosis. VDAC1 has gained importance in research due to its involvement in several pathological conditions including neurodegenerative diseases and cancer. The protein has a molecular weight of approximately 30-32 kDa and is also expressed in the plasma membrane where it establishes a novel level of apoptosis regulation via its redox activity .

Studying VDAC1 is particularly important because it serves as a convergence point for various cellular processes including energy metabolism, calcium homeostasis, and cell death pathways. Its interaction with proteins like amyloid beta (Aβ) in Alzheimer's disease makes it a valuable target for understanding disease mechanisms and developing potential therapeutic approaches .

How do VDAC1 antibodies help in distinguishing between VDAC isoforms?

While VDAC has at least three different isoforms in vertebrates (VDAC1, VDAC2, and VDAC3), specialized antibodies enable researchers to distinguish between these highly similar proteins. For instance, the monoclonal antibody N152B/23 specifically targets VDAC1 without cross-reacting with VDAC2 or VDAC3, as validated through knockout studies . This specificity is crucial for researchers investigating the distinct roles of VDAC1 compared to its other isoforms.

In contrast, some antibodies like PA1-954A detect all three VDAC isoforms because they target the C-terminal amino acid residues 185-197 of human VDAC3, a sequence completely conserved between isoforms 1, 2, and 3 of human VDAC . When conducting isoform-specific experiments, researchers should carefully validate antibody specificity through techniques such as:

• Western blot analysis with recombinant VDAC isoforms

• Testing in knockout cell lines lacking specific VDAC isoforms

• Peptide competition assays with isoform-specific peptides

What are the recommended applications for VDAC1 antibodies?

Based on validated research applications, VDAC1 antibodies are effectively used in multiple experimental approaches:

When performing Western blot analysis, researchers should expect to detect a single, prominent ~31 kDa band representing VDAC1 from tissue extracts such as rat heart .

How can researchers study VDAC1 interactions with amyloid beta in Alzheimer's disease models?

Recent evidence has demonstrated direct interactions between VDAC1 and amyloid beta (Aβ), which are implicated in Alzheimer's disease (AD) pathogenesis. To investigate these interactions, researchers can employ several methodological approaches:

• Co-immunoprecipitation (Co-IP): Using VDAC1 antibodies for immunoprecipitation followed by immunoblotting with Aβ antibodies (such as 6E10 for monomeric Aβ or A11 for oligomeric Aβ). This approach has successfully revealed interactions between VDAC1 and both 4 kDa Aβ and 100 kDa full-length APP in AD patients and AD mouse models .

• Double-labeling immunofluorescence analysis: This technique can visualize co-localization of VDAC1 with Aβ in tissue sections. Studies have demonstrated co-localization of VDAC1 immunoreactivity with both full-length APP and Aβ in frontal cortex sections from AD patients .

• Transgenic mouse models: Using brain tissues from AD mouse models such as APP, APP/PS1, or 3XTg.AD mice at appropriate ages (e.g., 20 months) to study the progressive interaction between VDAC1 and Aβ .

It's noteworthy that VDAC1 levels progressively increase as AD progresses through Braak stages, with significant increases observed even at early Braak stages I and II. This makes VDAC1 a potential biomarker for AD progression and a target for therapeutic intervention .

What methodological approaches can detect VDAC1 phosphorylation?

Phosphorylated VDAC1 appears as a distinct 60 kDa band in immunoblots, alongside the 32 kDa non-phosphorylated form. When investigating VDAC1 phosphorylation, researchers should consider:

• Antibody selection: Ensure the VDAC1 antibody can detect both phosphorylated and non-phosphorylated forms. Some antibodies like those from Bioss have demonstrated this capability in immunoprecipitation studies .

• Sample preparation: Phosphorylation status can be affected by sample handling. Use phosphatase inhibitors in lysis buffers to preserve phosphorylation.

• Control experiments: Include phosphatase treatment of parallel samples as a negative control to confirm the identity of the phosphorylated band.

• Co-immunoprecipitation studies: Phosphorylated VDAC1 may have different protein interaction profiles, which can be investigated using immunoprecipitation followed by immunoblotting for interacting partners .

How can VDAC1 antibodies be utilized to study its role in cancer research?

Recent studies have identified VDAC1 as a potential target for cancer therapy. To investigate VDAC1's role in cancer using antibodies, researchers can:

• Compare VDAC1 expression levels: Use Western blotting and immunohistochemistry to quantify VDAC1 expression in cancer versus normal tissues. This approach can help identify cancers where VDAC1 targeting might be therapeutically relevant .

• Study VDAC1 interactions with small molecule inhibitors: For example, VA (VDAC Antagonist) molecules that compete with NADH for binding to VDAC1 have shown promise in cancer treatment. Antibodies can be used to validate target engagement through techniques such as cellular thermal shift assays (CETSA) or immunoprecipitation followed by binding assays .

• Investigate VDAC1 in patient-derived organoids: VDAC1 antibodies can be used to confirm expression levels in organoid models derived from patients. Research has shown that cancer organoids (such as those from intrahepatic cholangiocarcinoma) express different levels of VDAC1 compared to healthy organoids, which correlates with sensitivity to VDAC1-targeting compounds .

• Visualize VDAC1 localization in cancer cells: Immunofluorescence using VDAC1 antibodies can reveal potential alterations in subcellular localization that might contribute to cancer-specific metabolic adaptations .

What controls should be included when performing VDAC1 immunoprecipitation experiments?

When conducting immunoprecipitation experiments with VDAC1 antibodies, the following controls are essential:

• Isotype control antibody: Use an irrelevant antibody of the same isotype (e.g., MIgG2a for N152B/23) to control for non-specific binding .

• Input samples: Always include an aliquot of the pre-immunoprecipitation lysate to confirm target protein expression.

• Knockout or knockdown validation: When available, include samples from VDAC1 knockout or knockdown cells/tissues to confirm antibody specificity. The N152B/23 antibody has been validated using knockout approaches .

• Immunizing peptide competition: For antibodies like PA1-954A, the immunizing peptide (e.g., Cat. # PEP-082) should be used in neutralization experiments to confirm specificity .

• Cross-validation with multiple antibodies: When studying novel interactions, confirm findings using different VDAC1 antibodies targeting distinct epitopes.

In interaction studies, reverse immunoprecipitation (using antibodies against the interacting protein followed by VDAC1 detection) provides additional validation of the interaction, as demonstrated in studies of VDAC1 interaction with Aβ .

What are the optimal conditions for using VDAC1 antibodies in immunofluorescence studies?

For successful immunofluorescence staining with VDAC1 antibodies, consider these methodological details:

• Fixation method: Paraformaldehyde (4%) is typically effective for preserving VDAC1 epitopes while maintaining cellular structure.

• Permeabilization: Since VDAC1 is found in both mitochondrial and plasma membranes, optimal permeabilization is crucial. A mild detergent like 0.1% Triton X-100 is generally suitable.

• Blocking solution: 5-10% normal serum from the species in which the secondary antibody was raised helps reduce background.

• Antibody dilution: For PA1-954A and N152B/23, follow manufacturer recommendations (typically 1:100 to 1:500 for immunofluorescence) .

• Co-staining considerations: When performing double-labeling experiments with VDAC1 and interacting proteins (such as Aβ or phosphorylated tau), ensure primary antibodies are from different host species to avoid cross-reactivity of secondary antibodies .

• Controls: Include a negative control omitting primary antibody and, when possible, a VDAC1 knockdown/knockout sample as specificity control.

How can researchers measure the binding affinity of molecules to VDAC1?

To determine binding affinities of molecules to VDAC1, researchers have successfully employed these techniques:

• Fluorescence polarization (FP): This approach has been used to measure NADH binding to purified VDAC1, yielding an apparent affinity (KD) of 6.80 ± 0.06 μM. For competition assays with other molecules like VA compounds, researchers maintain a fixed NADH concentration (e.g., 5μM) and add increasing concentrations of the competing molecule .

• Competition binding assays: These have demonstrated that VA molecules compete with NADH for binding to VDAC1 with apparent KD values in the micromolar range:

  • VA-D11: KD = 15.9 ± 0.7 μM

  • VA-D10: KD = 18.5 ± 0.2 μM

  • VA-C1: KD = 18.7 ± 0.3 μM

  • VA-C4: KD = 19.4 ± 0.4 μM

  • VA-C6: KD = 18.7 ± 0.6 μM

• Site-directed mutagenesis: Mutations in key VDAC1 residues identified through docking simulations can confirm binding sites and test the importance of specific interactions. This approach helps validate in silico predictions about molecule binding to VDAC1 .

What are the best practices for storing and handling VDAC1 antibodies?

To maintain optimal activity of VDAC1 antibodies, follow these storage and handling recommendations:

• Short-term storage: For immediate use within two weeks, store at 4°C .

• Long-term storage: For extended periods, divide into small aliquots (minimum 20 μl) and store at -20°C or -80°C to avoid repeated freeze-thaw cycles which can degrade antibody performance .

• Cryoprotection: For concentrated antibody products, consider adding an equal volume of glycerol as a cryoprotectant before freezing .

• Working dilutions: Prepare only the amount needed for immediate experiments. Diluted antibody solutions have reduced stability.

• Contamination prevention: Use sterile technique when handling antibody solutions to prevent microbial growth.

How can VDAC1 antibodies help investigate its role in neurodegenerative diseases?

VDAC1 antibodies have been instrumental in revealing the protein's involvement in neurodegenerative diseases, particularly Alzheimer's disease (AD):

• Tracking disease progression: Immunoblotting with VDAC1 antibodies has demonstrated that VDAC1 protein levels progressively increase as AD advances through Braak stages, correlating with disease severity .

• Studying protein-protein interactions: Co-immunoprecipitation with VDAC1 antibodies has revealed interactions with disease-relevant proteins:

  • Amyloid beta (both monomeric and oligomeric forms)

  • Full-length APP

  • Phosphorylated tau

• Visualizing pathological associations: Double-labeling immunofluorescence using VDAC1 antibodies together with antibodies against Aβ or phosphorylated tau has demonstrated co-localization in AD brain tissue sections and in 3XTg.AD mouse models .

• Therapeutic target validation: In VDAC1+/- mice, reduced VDAC1 expression correlates with protection against AD-related toxicities, suggesting VDAC1 as a potential therapeutic target. Antibodies help characterize this protective mechanism by showing reduced ROS production, decreased lipid peroxidation, and elevated ATP levels in these models .

What experimental approaches can determine if VDAC1 antibodies affect channel function?

To investigate whether VDAC1 antibodies impact channel functionality, researchers can employ these experimental approaches:

• Electrophysiological measurements: Reconstitute purified VDAC1 in planar lipid bilayers and measure channel conductance before and after antibody addition. Changes in conductance may indicate functional modulation by the antibody.

• Mitochondrial permeability assays: Measure the effect of VDAC1 antibodies on isolated mitochondria's permeability to metabolites such as ADP/ATP, possibly revealing functional consequences of antibody binding.

• Cellular ATP levels: Determine whether treatment of permeabilized cells with VDAC1 antibodies affects cellular ATP production, which depends on efficient VDAC1-mediated transport of metabolites.

• ROS production measurement: Since VDAC1 is implicated in mitochondrial ROS regulation, measuring changes in ROS levels following antibody treatment can indicate functional effects .

• Mitochondrial respiratory analysis: Using oxygen consumption rate (OCR) measurements to assess whether VDAC1 antibodies affect mitochondrial respiration, which would suggest functional modulation of the channel.

What strategies can resolve non-specific binding issues with VDAC1 antibodies?

When encountering non-specific binding with VDAC1 antibodies, consider these troubleshooting approaches:

• Antibody validation: Confirm antibody specificity using VDAC1 knockout samples or peptide competition assays with the immunizing peptide (e.g., PEP-082 for PA1-954A) .

• Blocking optimization: Increase blocking reagent concentration or try different blocking agents (BSA, normal serum, commercial blockers) to reduce non-specific binding.

• Antibody dilution: Test a range of antibody dilutions to find the optimal concentration that maximizes specific signal while minimizing background.

• Cross-reactivity assessment: If using multiple antibodies (e.g., in co-localization studies), ensure secondary antibodies don't cross-react with primary antibodies from different species.

• Sample preparation: Optimize fixation and permeabilization protocols, as excessive or insufficient treatment can expose epitopes that contribute to non-specific binding.

• Alternative VDAC1 antibodies: If possible, compare results using different VDAC1 antibodies that target distinct epitopes, such as N152B/23 (specific for VDAC1) versus PA1-954A (detects all VDAC isoforms) .

How can researchers differentiate between mitochondrial and plasma membrane VDAC1?

VDAC1 is present in both mitochondrial outer membrane and plasma membrane locations, which can complicate experimental interpretation. To distinguish between these populations:

• Subcellular fractionation: Separate mitochondrial and plasma membrane fractions using gradient centrifugation prior to immunoblotting with VDAC1 antibodies.

• Co-localization studies: Perform double immunofluorescence labeling with VDAC1 antibodies and established markers for:

  • Mitochondria (e.g., TOMM20, MitoTracker dyes)

  • Plasma membrane (e.g., Na+/K+-ATPase, WGA)

• Non-permeabilized cell staining: In intact, non-permeabilized cells, VDAC1 antibodies will only detect plasma membrane VDAC1, while permeabilization is required to visualize mitochondrial VDAC1.

• Function-based approaches: Plasma membrane VDAC1 facilitates Aβ penetration into cells, which can be used as a functional assay to study this specific pool. For example, treatment with plasma membrane-impermeable VDAC1 antibodies might selectively affect Aβ uptake without impacting mitochondrial functions .